| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Translational Therapeutics at the Platelet Vascular Interface: A CME-Certified Activity |
From the University of Pennsylvania, Department of Medicine, Division of Hematology-Oncology, Philadelphia.
Correspondence to Lawrence Brass, University of Pennsylvania, Room 915 BRB-II, 421 Curie Blvd, Philadelphia, PA 19104. E-mail Brass{at}mail.med.upenn.edu
Abstract
Platelet activation in vivo can be part of the hemostatic response to injury or a pathological response to disease. In either setting, platelets adhere to the vessel wall and to each other, forming a closely packed mass interspersed with fibrin. Recent studies have identified new molecules on the platelet surface and within platelets that support and regulate thrombus growth and stability, ensuring that platelet accumulation after injury is sufficient to stop bleeding, but not so exuberant that vascular occlusion occurs. An understanding of how this balance is achieved helps to illuminate the events of platelet activation and, at the same time, provides potential targets for new classes of antiplatelet agents.
Key Words: platelets cell adhesion molecules integrins semaphorins ephrins Eph kinases vascular biology
This article has been cited by other articles:
![]() |
A. Ono, E. Westein, S. Hsiao, W. S. Nesbitt, J. R. Hamilton, S. M. Schoenwaelder, and S. P. Jackson Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth Blood, July 1, 2008; 112(1): 90 - 99. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |